High NF-E2-related factor 2 expression predicts poor prognosis in patients with lung cancer: a meta-analysis of cohort studies

References

• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132.
   PubMed Web of Science ®Google Scholar
• Roh MS. Molecular pathology of lung cancer: current status and future directions. Tuberc Respir Dis (Seoul). 2014;77(2):49–54.
   PubMedGoogle Scholar
• Shtivelman E, Hensing T, Simon GR, et al. Molecular pathways and therapeutic targets in lung cancer. Oncotarget. 2014;5(6):1392–1433.
   PubMed Web of Science ®Google Scholar
• Frezzetti D, Gallo M, Maiello MR, et al. VEGF as a potential target in lung cancer. Expert Opin Ther Targets. 2017;21(10):959–966.
   PubMed Web of Science ®Google Scholar
• Povedano JM, Martinez P, Serrano R, et al. Therapeutic effects of telomerase in mice with pulmonary fibrosis induced by damage to the lungs and short telomeres. ELife. 2018;7:e31299.
   PubMed Web of Science ®Google Scholar
• Ariyasu R, Nishikawa S, Uchibori K, et al. High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer. Lung Cancer. 2018;117:1–6.
   PubMed Web of Science ®Google Scholar
• Corre R, Gervais R, Guisier F, et al. Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study). Oncotarget. 2018;9(9):8253–8262.
   PubMedGoogle Scholar
• Okamoto I, Morita S, Tashiro N, et al. Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: long-term follow-up of a large patient cohort. Lung Cancer. 2018;117:14–19.
   PubMed Web of Science ®Google Scholar
• Zhang B, Xu J, Zhang X, et al. Coexistence of sensitive and resistant epidermal growth factor receptor (EGFR) mutations in pretreatment non-small cell lung cancer (NSCLC) patients: first or third generation tyrosine kinase inhibitors (TKIs)? Lung Cancer. 2018;117:27–31.
   PubMed Web of Science ®Google Scholar
• Jiang T, Qiao M, Zhao C, et al. Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis. Cancer Immunol Immunother. 2018;67(5):713–727.
   PubMed Web of Science ®Google Scholar
• Bačić I, Karlo R, Zadro AŠ, et al. Tumor angiogenesis as an important prognostic factor in advanced non-small cell lung cancer (stage IIIA). Oncol Lett. 2018;15(2):2335–2339.
   PubMed Web of Science ®Google Scholar
• Gerber DE, Socinski MA, Neal JW, et al. Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. Lung Cancer. 2018;117:44–49.
   PubMed Web of Science ®Google Scholar
• Mehrad M, Roy S, LaFramboise WA, et al. KRAS mutation is predictive of outcome in patients with pulmonary sarcomatoid carcinoma. Histopathology. 2018;73(2):207–214.
   PubMed Web of Science ®Google Scholar
• Román M, Baraibar I, López I, et al. KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. Mol Cancer. 2018;17(1):33.
   PubMedGoogle Scholar
• Kalemkerian GP, Narula N, Kennedy EB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice guideline update. J Clin Oncol. 2018;36(9):911–919.
   PubMed Web of Science ®Google Scholar
• Vargas AJ, Harris CC. Biomarker development in the precision medicine era: lung cancer as a case study. Nat Rev Cancer. 2016;16(8):525–537.
   PubMed Web of Science ®Google Scholar
• Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Mol Diagn. 2018;20(2):129–159.
   PubMed Web of Science ®Google Scholar
• Solis LM, Behrens C, Dong W, et al. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res. 2010;16(14):3743–3753.
   PubMed Web of Science ®Google Scholar
• Yang H, Wang W, Zhang Y, et al. The role of NF-E2-related factor 2 in predicting chemoresistance and prognosis in advanced non-small-cell lung cancer. Clin Lung Cancer. 2011;12(3):166–171.
   PubMed Web of Science ®Google Scholar
• Cao B, Yin W, Zhu X, et al. The role of expression of Nrf2 in predicting chemoresistance and prognosis in advanced non-small cell lung cancer receiving platinum-based first-line chemotherapy. Tumor. 2012;32:919–924.
   Google Scholar
• Inoue D, Suzuki T, Mitsuishi Y, et al. Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma. Cancer Sci. 2012;103(4):760–766.
   PubMed Web of Science ®Google Scholar
• Merikallio H, Pääkkö P, Kinnula VL, et al. Nuclear factor erythroid-derived 2-like 2 (Nrf2) and DJ1 are prognostic factors in lung cancer. Hum Pathol. 2012;43(4):577–584.
   PubMed Web of Science ®Google Scholar
• Ishikawa T. Genetic polymorphism in the NRF2 gene as a prognosis marker for cancer chemotherapy. Front Genet. 2014;5:383.
   PubMed Web of Science ®Google Scholar
• Zhu X, Liang L, Liu C, et al. [Role of the expression level of Nrf2 in predicting response of EGFR-TKIs in lung adenocarcinoma patients with EGFR gene mutations]. Zhongguo Fei Ai Za Zhi. 2014;17(2):155–162.
   PubMedGoogle Scholar
• Cescon DW, She D, Sakashita S, et al. NRF2 pathway activation and adjuvant chemotherapy benefit in lung squamous cell carcinoma. Clin Cancer Res. 2015;21(11):2499–2505.
   PubMed Web of Science ®Google Scholar
• Qian Z, Zhou T, Gurguis CI, et al. Nuclear factor, erythroid 2-like 2-associated molecular signature predicts lung cancer survival. Sci Rep. 2015;5:16889.
   PubMed Web of Science ®Google Scholar
• Tian Y, Liu Q, He X, et al. Emerging roles of Nrf2 signal in non-small cell lung cancer. J Hematol Oncol. 2016;9:14.
   PubMed Web of Science ®Google Scholar
• Tong YH, Zhang B, Yan YY, et al. Dual-negative expression of Nrf2 and NQO1 predicts superior outcomes in patients with non-small cell lung cancer. Oncotarget. 2017;8(28):45750–45758.
   PubMedGoogle Scholar
• Xiang M, Namani A, Wu S, et al. Nrf2: bane or blessing in cancer? J Cancer Res Clin Oncol. 2014;140(8):1251–1259.
   PubMed Web of Science ®Google Scholar
• Vomund S, Schäfer A, Parnham MJ, et al. Nrf2, the master regulator of anti-oxidative responses. Int J Mol Sci. 2017;18(12): E2772.
   PubMed Web of Science ®Google Scholar
• Kitamura H, Motohashi H. NRF2 addiction in cancer cells. Cancer Sci. 2018;109(4):900–911.
   PubMed Web of Science ®Google Scholar
• Menegon S, Columbano A, Giordano S. The dual roles of NRF2 in cancer. Trends Mol Med. 2016;22(7):578–593.
   PubMed Web of Science ®Google Scholar
• Saito T, Ichimura Y, Taguchi K, et al. p62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming. Nat Commun. 2016;7:12030.
   PubMed Web of Science ®Google Scholar
• Wu YS, Looi CY, Subramaniam KS, et al. Soluble factors from stellate cells induce pancreatic cancer cell proliferation via Nrf2-activated metabolic reprogramming and ROS detoxification. Oncotarget. 2016;7(24):36719–36732.
   PubMed Web of Science ®Google Scholar
• Kitano Y, Baba Y, Nakagawa S, et al. Nrf2 promotes oesophageal cancer cell proliferation via metabolic reprogramming and detoxification of reactive oxygen species. J Pathol. 2018;244(3):346–357.
   PubMed Web of Science ®Google Scholar
• Mitsuishi Y, Taguchi K, Kawatani Y, et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell. 2012;22(1):66–79.
   PubMed Web of Science ®Google Scholar
• Niture SK, Jaiswal AK. Nrf2-induced antiapoptotic Bcl-xL protein enhances cell survival and drug resistance. Free Radic Biol Med. 2013;57:119–131.
   PubMed Web of Science ®Google Scholar
• Niture SK, Jaiswal AK. Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. J Biol Chem. 2012;287(13):9873–9886.
   PubMed Web of Science ®Google Scholar
• Milkovic L, Zarkovic N, Saso L. Controversy about pharmacological modulation of Nrf2 for cancer therapy. Redox Biol. 2017;12:727–732.
   PubMed Web of Science ®Google Scholar
• Tian B, Lu ZN, Guo XL. Regulation and role of nuclear factor-E2-related factor 2 (Nrf2) in multidrug resistance of hepatocellular carcinoma. Chem Biol Interact. 2018;280:70–76.
   PubMed Web of Science ®Google Scholar
• Cort A, Ozben T, Saso L, et al. Redox control of multidrug resistance and its possible modulation by antioxidants. Oxid Med Cell Longev. 2016;2016:4251912.
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8(0):16.
   PubMedGoogle Scholar
• Tierney J, Burdett S, et al. Assessing and improving the reliability of meta-analyses of hazard ratios derived from published time-to-event data. Trials. 2013;14(1):1–1.
   PubMedGoogle Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188.
   PubMedGoogle Scholar
• Yang X, Wang D, Ma Y, et al. Continuous activation of Nrf2 and its target antioxidant enzymes leads to arsenite-induced malignant transformation of human bronchial epithelial cells. Toxicol Appl Pharmacol. 2015;289(2):231–239.
   PubMed Web of Science ®Google Scholar
• Motohashi H, Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med. 2004;10(11):549–557.
   PubMed Web of Science ®Google Scholar
• Hayes JD, McMahon M, Chowdhry S, et al. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid Redox Signal. 2010;13(11):1713–1748.
   PubMed Web of Science ®Google Scholar
• Zhang P, Singh A, Yegnasubramanian S, et al. Loss of kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther. 2010;9(2):336–346.
   PubMed Web of Science ®Google Scholar
• Wang DP, Ma Y, Yang X, et al. Hypermethylation of the Keap1 gene inactivates its function, promotes Nrf2 nuclear accumulation, and is involved in arsenite-induced human keratinocyte transformation. Free Radic Biol Med. 2015;89(5):209–219.
   PubMedGoogle Scholar
• Taguchi K, Motohashi H, Yamamoto M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells. 2011;16(2):123–140.
   PubMed Web of Science ®Google Scholar
• Yamadori T, Ishii Y, Homma S, et al. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers. Oncogene. 2012;31(45):4768–4777.
   PubMed Web of Science ®Google Scholar
• Tao S, Wang S, Moghaddam SJ, et al. Oncogenic KRAS confers chemoresistance by upregulating NRF2. Cancer Res. 2014;74(24):7430–7441.
   PubMed Web of Science ®Google Scholar
• Yates MS, Tran QT, Dolan PM, et al. Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice. Carcinogenesis. 2009;30(6):1024–1031.
   PubMed Web of Science ®Google Scholar
• Kitteringham NR, Abdullah A, Walsh J, et al. Proteomic analysis of Nrf2 deficient transgenic mice reveals cellular defence and lipid metabolism as primary Nrf2-dependent pathways in the liver. J Proteomics. 2010;73(8):1612–1631.
   PubMed Web of Science ®Google Scholar
• Homma S, Ishii Y, Morishima Y, et al. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res. 2009;15(10):3423–3432.
   PubMed Web of Science ®Google Scholar
• Fojo T, Bates S. Strategies for reversing drug resistance. Oncogene. 2003;22(47):7512–7523.
   PubMed Web of Science ®Google Scholar
• Yao KS, Godwin AK, Johnson SW, et al. Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res. 1995;55(19):4367–4374.
   PubMed Web of Science ®Google Scholar
• Jeong HS, Ryoo IG, Kwak MK. Regulation of the expression of renal drug transporters in KEAP1-knockdown human tubular cells. Toxicol In Vitro. 2015;29(5):884–892.
   PubMed Web of Science ®Google Scholar
• Chen WM, Sun Z, Wang XJ, et al. Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol Cell. 2009;34(6):663–673.
   PubMed Web of Science ®Google Scholar
• Ma J, Cai H, Wu T, et al. PALB2 interacts with KEAP1 to promote NRF2 nuclear accumulation and function. Mol Cell Biol. 2012;32(8):1506–1517.
   PubMed Web of Science ®Google Scholar
• Satoh H, Moriguchi T, Taguchi K, et al. Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung. Carcinogenesis. 2010;31(10):1833–1843.
   PubMed Web of Science ®Google Scholar
• Iizuka T, Ishii Y, Itoh K, et al. Nrf2-deficient mice are highly susceptible to cigarette smoke-induced emphysema. Genes Cells. 2005;10(12):1113–1125.
   PubMed Web of Science ®Google Scholar